CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

T-Cell Fuel Source, Chemotherapy Exposure Reduce Potential to Develop CAR-T Therapy

March 15th 2018

Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor T-cell therapy.

Dr. Bachier Discusses CAR T-Cell Therapy and Stem Cell Transplant

March 13th 2018

Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.

Dr. Brentjens Discusses the Goal of Armored CAR T Cells

March 9th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.

Research Strategies to Improve Outcomes in GBM

March 5th 2018

GBM Emerging Strategies in Immunotherapy

March 5th 2018

GBM Rationale for Combining PD1 Inhibitor DNA Vaccine

March 5th 2018

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Perl Highlights Latest CAR T-Cell Therapy Advances

March 5th 2018

Alexander Perl, MD, discusses the implementation of CAR T-cell therapy in ALL and other advances with this unique treatment across the spectrum of hematologic malignancies.

Dr. Perl Discusses the Impact of the ELIANA Trial

March 1st 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of the ELIANA trial in acute lymphoblastic leukemia (ALL).

How Durable Are CAR T-Cell Therapies?

March 1st 2018

The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.

Bright Future for Gene Therapy in Hematologic Malignancies

February 28th 2018

A panel of experts discusses the current state of CAR T-cell therapies and sheds light on the future directions of this therapeutic approach.

Dr. Perl Discusses Upcoming CAR T-Cell Therapies for ALL

February 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses upcoming chimeric antigen receptor (CAR) T-cell therapies for patients with acute lymphoblastic leukemia (ALL).

Dr. Perl Discusses the Impact of CAR T-Cell Therapy on ALL

February 16th 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with acute lymphoblastic leukemia (ALL).

Dr. Shah on Cellular Therapies for Patients With Myeloma

February 12th 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor T-cell therapy in myeloma.

Dr. Andreadis Discusses Toxicities With CAR T-Cell Therapy

February 8th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses toxicities associated with CAR T-cell therapy.

Dr. Brentjens Discusses Toxicities Associated With CAR T-Cell Therapy

February 5th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.

Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

February 3rd 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.